Niitaka achieved sales of JPY 24,619 million (3.8% increase) and operating profit of JPY 2,118 million (10.1% increase) for the fiscal year ending May 2026. The Chemical segment performed well due to steady food service demand and expanded high-value products, while the Healthcare segment saw decreased revenue but maintained profitability through cost reductions. For the current period, revenue is projected at JPY 27.5 billion with a net profit of JPY 1.28 billion.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4465","jir_company_name":"Niitaka Corporation","jir_importance":"\u2605\u2605\u2605\u2605\u2605","jir_publication_date":"2026-07-13","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/07\/4465-20260713-01.pdf","jir_short_summary":"Niitaka achieved sales of JPY 24,619 million (3.8% increase) and operating profit of JPY 2,118 million (10.1% increase) for the fiscal year ending May 2026. The Chemical segment performed well due to steady food service demand and expanded high-value products, while the Healthcare segment saw decreased revenue but maintained profitability through cost reductions. For the current period, revenue is projected at JPY 27.5 billion with a net profit of JPY 1.28 billion.","jir_summary":"### Overview of Financial Results\nNiitaka achieved sales of JPY 24,619 million (YoY +3.8%) and operating profit of JPY 2,118 million (10.1% increase) for the fiscal year ending May 2026. The Chemical segment remained robust due to steady demand in the food service industry and sales expansion of high-value-added products. Meanwhile, the Healthcare segment experienced decreased revenue amid declining domestic and international demand but secured profits through cost reductions. The company forecasts sales of JPY 27.5 billion and net profit of JPY 1.28 billion for the current period, continuing to focus on profit sharing and business expansion.\n\n### Future Outlook and Impact on Shareholders\nGoing forward, Niitaka will respond to external environmental changes while maintaining profitability in the Chemical segment supported by steady demand. The Healthcare segment will aim for long-term growth through overseas expansion and new product development. The dividend will be increased to JPY 39, with a planned total of JPY 84 for interim and year-end payments in the next period. The company emphasizes shareholder return and promotes a balanced approach to capital policy and business strategy.","jir_financial_highlights":"Revenue: JPY 24,619 million (YoY +3.8\uff05)\nOperating Profit: JPY 2,118 million (YoY +10.1\uff05)\nNet Income attributable to owners of parent: JPY 1,900 million (YoY +5.3\uff05)\nEquity Ratio: 68.2\uff05 (Compared to the previous period +2.9 percentage points)\nDividend: JPY 39 (ending) (Compared to the previous period +1 yen)","jir_category":"","jir_hashtags":"#Niitaka, #IRFinancialResults, #JapanStocks","jir_key_figures":"Revenue: JPY 24,619 million (YoY +3.8%)\nOperating Profit: JPY 2,118 million (YoY +10.1%)\nNet Income attributable to owners of parent: JPY 1,900 million (YoY +5.3%)","jir_meta_title":"\u3010Niitaka\u30112026 Financial Results \uff5c Revenue of JPY 2.46 billion, Increasing Revenue and Profit","jir_meta_description":"Niitaka achieved sales of JPY 24,619 million and operating profit of JPY 2,118 million for fiscal year 2026. The company forecasts revenue of JPY 27.5 billion and net profit of JPY 1.28 billion, with strengthened shareholder returns.","jir_og_title":"\u3010Niitaka\u30112026 Financial Results \uff5c Revenue of JPY 2.46 billion, Increasing Revenue and Profit","jir_og_description":"Niitaka reports sales of JPY 2.46 billion and profit growth in FY 2026. The company continues to promote business expansion and shareholder returns.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Revenue Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"FY 2025\\\", \\\"FY 2026\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Revenue\\\", \\\"data\\\": [23714, 24619], \\\"borderColor\\\": \\\"#36A2EB\\\", \\\"fill\\\": false}]} \"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Profit Trend\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"FY 2025\\\", \\\"FY 2026\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Operating Profit\\\", \\\"data\\\": [1925, 2118], \\\"borderColor\\\": \\\"#4BC0C0\\\", \\\"fill\\\": false}]} \"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"pie\", \"jir_chart_title\": \"Segment Revenue Breakdown\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Chemical Business\\\", \\\"Healthcare Business\\\"], \\\"datasets\\\": [{\\\"data\\\": [23267, 1351], \\\"backgroundColor\\\": [\\\"#FF6384\\\", \\\"#FFCE56\\\"]}]} \"}, {\"jir_chart_id\": \"margin_analysis\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Profit Margin Analysis\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"Chemical Business\\\", \\\"Healthcare Business\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Operating Profit Margin\\\", \\\"data\\\": [8.2, 15.7], \\\"backgroundColor\\\": [\\\"#36A2EB\\\", \\\"#FF6384\\\"]}]} \"}, {\"jir_chart_id\": \"guidance_comparison\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Forecast vs Actual Comparison\", \"jir_chart_json_data\": \"{\\\"labels\\\": [\\\"FY 2026 Actual\\\", \\\"FY 2027 Forecast\\\"], \\\"datasets\\\": [{\\\"label\\\": \\\"Revenue\\\", \\\"data\\\": [24619, 27500], \\\"backgroundColor\\\": \\\"#4BC0C0\\\"}, {\\\"label\\\": \\\"Net Profit\\\", \\\"data\\\": [1900, 1285], \\\"backgroundColor\\\": \\\"#FF6384\\\"}]} \"}]","ir_related_company":58419,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-79914","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n